(Q37259258)

19 August 2017

1 reference

title

Recent advances in treating cognitive impairment in schizophrenia (English)

1 reference

19 August 2017

0 references

cognitive dysfunction

1 reference

Cherrie Galletly

1

1 reference

19 August 2017

publication date

3 September 2008

1 reference

19 August 2017

number of pages

15

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

19 August 2017

volume

202

1 reference

19 August 2017

issue

1-3

1 reference

19 August 2017

page(s)

259-273

1 reference

https://scigraph.springernature.com/pub.10.1007/s00213-008-1302-9

19 August 2017

exact match

0 references

cites work

Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Childhood antecedents of schizophrenia and affective illness: social adjustment at ages 7 and 11

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Chart-recorded psychiatric diagnoses in women giving birth in California in 1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

The dopamine hypothesis of schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Quality of life as a predictor for change in disability in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-008-1302-9

Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia

21 January 2018

1 reference

12 December 2020

Relationship between drug company funding and outcomes of clinical psychiatric research

1 reference

12 December 2020

Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo

1 reference

12 December 2020

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

1 reference

12 December 2020

Cognition as an outcome measure in schizophrenia.

1 reference

12 December 2020

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

1 reference

12 December 2020

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

1 reference

12 December 2020

Identification of separable cognitive factors in schizophrenia

1 reference

12 December 2020

Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology

1 reference

12 December 2020

Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism

1 reference

12 December 2020

Impact of modafinil on prefrontal executive function in schizophrenia.

1 reference

12 December 2020

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms

1 reference

12 December 2020

1 reference

12 December 2020

Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism

1 reference

12 December 2020

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

1 reference

12 December 2020

Biological, life course, and cross-cultural studies all point toward the value of dimensional and developmental ratings in the classification of psychosis

1 reference

12 December 2020

Verbal memory, negative symptomatology and prediction of psychosocial functioning in schizophrenia

1 reference

12 December 2020

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

1 reference

12 December 2020

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

1 reference

12 December 2020

Towards a muscarinic hypothesis of schizophrenia.

1 reference

12 December 2020

Treating cognitive dysfunction in patients with schizophrenia

1 reference

12 December 2020

The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls

1 reference

12 December 2020

Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia

1 reference

12 December 2020

The molecular genetics of schizophrenia: new findings promise new insights

1 reference

12 December 2020

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

1 reference

12 December 2020

Normalization of auditory physiology by cigarette smoking in schizophrenic patients

1 reference

12 December 2020

Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia

1 reference

12 December 2020

Catechol O -methyltransferase val 158 -met genotype and individual variation in the brain response to amphetamine

1 reference

12 December 2020

Longitudinal studies of cognition in schizophrenia: meta-analysis

1 reference

12 December 2020

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

1 reference

12 December 2020

Social perception as a mediator of the influence of early visual processing on functional status in schizophrenia.

1 reference

12 December 2020

The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

1 reference

12 December 2020

Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits

1 reference

12 December 2020

Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort

1 reference

12 December 2020

Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia.

1 reference

12 December 2020

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

12 December 2020

Predictive value of cognition for different domains of outcome in recent-onset schizophrenia

1 reference

12 December 2020

How should DSM-V criteria for schizophrenia include cognitive impairment?

1 reference

12 December 2020

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

1 reference

12 December 2020

Low levels of alpha7-nicotinic acetylcholine receptor mRNA on peripheral blood lymphocytes in schizophrenia and its association with illness severity

1 reference

12 December 2020

Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature

1 reference

12 December 2020

Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats.

1 reference

12 December 2020

IQ and risk for schizophrenia: a population-based cohort study.

1 reference

12 December 2020

Nicotinic receptor desensitization and sensory gating deficits in schizophrenia

1 reference

12 December 2020

Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment

1 reference

12 December 2020

Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study

1 reference

12 December 2020

M100907, a serotonin 5-HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague-Dawley and Wistar rats

1 reference

12 December 2020

A review of the effects of modafinil on cognition in schizophrenia

1 reference

12 December 2020

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

1 reference

12 December 2020

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Catechol-O-methyltransferase genotype and dopamine regulation in the human brain.

1 reference

12 December 2020

Cholinergic enhancement and increased selectivity of perceptual processing during working memory.

1 reference

12 December 2020

Cognitive enhancing effects of modafinil in healthy volunteers

1 reference

12 December 2020

Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia

1 reference

12 December 2020

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

1 reference

12 December 2020

Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.

1 reference

12 December 2020

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients

1 reference

12 December 2020

Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates

1 reference

12 December 2020

Cholinesterase inhibitors for Alzheimer's disease

1 reference

12 December 2020

The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period

1 reference

12 December 2020

Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia

1 reference

12 December 2020

Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial

1 reference

12 December 2020

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

1 reference

12 December 2020

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

12 December 2020

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

1 reference

12 December 2020

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

1 reference

12 December 2020

Financial implications of cigarette smoking among individuals with schizophrenia

1 reference

12 December 2020

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

1 reference

12 December 2020

5-hydroxytryptamine2A receptor inverse agonists as antipsychotics

1 reference

12 December 2020

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

1 reference

12 December 2020

Cognitive improvement during Tolcapone treatment in Parkinson's disease.

1 reference

12 December 2020

Social functioning and neurocognitive deficits in outpatients with schizophrenia: a 2-year follow-up

1 reference

12 December 2020

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative

1 reference

12 December 2020

Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation

1 reference

12 December 2020

Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism

1 reference

12 December 2020

Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

1 reference

12 December 2020

A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats

1 reference

12 December 2020

Smoking and therapeutic response to clozapine in patients with schizophrenia

1 reference

12 December 2020

Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers

1 reference

12 December 2020

Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance.

1 reference

12 December 2020

Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory

1 reference

12 December 2020

Galantamine for the treatment of cognitive impairments in people with schizophrenia

1 reference

12 December 2020

Characterization of allelic variants at chromosome 15q14 in schizophrenia

1 reference

12 December 2020

Clozapine improves working memory updating in schizophrenia

1 reference

12 December 2020

Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving

1 reference

12 December 2020

Cognitive functioning predicts outpatient service utilization in schizophrenia.

1 reference

12 December 2020

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

12 December 2020

Effects of nicotine nasal spray on cognitive function in schizophrenia

1 reference

12 December 2020

Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland

1 reference

12 December 2020

The effects of clonidine on discrete-trial delayed spatial alternation in two rat models of memory loss

1 reference

12 December 2020

Storage and executive processes in the frontal lobes

1 reference

12 December 2020

A meta-analysis of cognitive remediation in schizophrenia

1 reference

12 December 2020

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

1 reference

12 December 2020

In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia

1 reference

12 December 2020

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

1 reference

12 December 2020

The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity

1 reference

12 December 2020

Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior

1 reference

12 December 2020

The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

1 reference

12 December 2020

Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus

1 reference

12 December 2020

A model of anticholinergic activity of atypical antipsychotic medications

1 reference

12 December 2020

The role of cognition in vocational functioning in schizophrenia.

1 reference

12 December 2020

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

1 reference

12 December 2020

A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

1 reference

12 December 2020

Impaired updating of working memory in schizophrenia.

1 reference

12 December 2020

Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative

1 reference

12 December 2020

Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study

1 reference

12 December 2020

Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions.

1 reference

12 December 2020

Guanfacine treatment of cognitive impairment in schizophrenia

1 reference

12 December 2020

Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study

1 reference

12 December 2020

Functional magnetic resonance imaging studies of eye movements in first episode schizophrenia: smooth pursuit, visually guided saccades and the oculomotor delayed response task.

1 reference

12 December 2020

Cognition in schizophrenia

1 reference

12 December 2020

Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.

1 reference

12 December 2020

Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry

1 reference

12 December 2020

The effects of neuroleptics on neuropsychological test results of schizophrenics.

1 reference

12 December 2020

Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia

1 reference

12 December 2020

The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication.

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

1 reference

12 December 2020

5HT antagonists attenuate MK801-impaired radial arm maze performance in rats.

1 reference

12 December 2020

The CATIE schizophrenia trial: results, impact, controversy

1 reference

12 December 2020

Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission.

1 reference

12 December 2020

Child development risk factors for adult schizophrenia in the British 1946 birth cohort

1 reference

12 December 2020

Computer-aided cognitive rehabilitation: possible application to the attentional deficit of schizophrenia, a report of negative results

1 reference

12 December 2020

Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

1 reference

12 December 2020

Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients

1 reference

12 December 2020

COMT inhibitors and liver toxicity.

1 reference

12 December 2020

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia.

1 reference

12 December 2020

The effect of galantamine added to clozapine on cognition of five patients with schizophrenia

1 reference

12 December 2020

Is clonidine useful for treatment of clozapine-induced sialorrhea?

1 reference

12 December 2020

Clonidine improves memory function in schizophrenia independently from change in psychosis. Preliminary findings.

1 reference

12 December 2020

Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates

1 reference

12 December 2020

3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner

1 reference

12 December 2020

Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers

1 reference

12 December 2020

Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia.

1 reference

12 December 2020

Social and clinical consequences of cognitive deficits in early psychosis: a two-year follow-up study of first-admitted patients.

1 reference

12 December 2020

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

1 reference

12 December 2020

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

1 reference

12 December 2020

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

1 reference

12 December 2020

Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia

1 reference

12 December 2020

Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes.

1 reference

12 December 2020

The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine

1 reference

12 December 2020

Metabotropic glutamate receptor agonists for schizophrenia

1 reference

12 December 2020

Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement?

1 reference

12 December 2020

A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia

1 reference

12 December 2020

A systematic review of modafinil: Potential clinical uses and mechanisms of action

1 reference

12 December 2020

Muscarinic receptors as a target for drugs treating schizophrenia

1 reference

12 December 2020

Glycine transport inhibitors and the treatment of schizophrenia

1 reference

12 December 2020

Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine

1 reference

12 December 2020

Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity

1 reference

12 December 2020

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

1 reference

12 December 2020

Initial phase 2 trial of a nicotinic agonist in schizophrenia

1 reference

12 December 2020

Cognitive remediation therapy in schizophrenia: randomised controlled trial

1 reference

12 December 2020

Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction

1 reference

12 December 2020

Does dopamine play a role in schizophrenia?

1 reference

12 December 2020

Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization

1 reference

12 December 2020

Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia

1 reference

12 December 2020

Pharmacological treatment of cognition in schizophrenia: an idea whose method has come

1 reference

12 December 2020

Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol

1 reference

12 December 2020

The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study

1 reference

12 December 2020

Population-based cohort studies on premorbid cognitive function in schizophrenia.

1 reference

12 December 2020

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

12 December 2020

10.1007/S00213-008-1302-9

Identifiers

DOI

1 reference

19 August 2017

1 reference